icotinib + chemotherapy (Betta Pharmaceuticals)

Icotinib + chemotherapy is a combination regimen developed by Betta Pharmaceuticals for the treatment of non-small cell lung cancer (NSCLC). The regimen consists of icotinib, an orally active, highly selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), administered alongside standard chemotherapy agents such as docetaxel or pemetrexed. This combination is primarily investigated for patients with locally advanced or metastatic NSCLC who have developed resistance to prior icotinib monotherapy (icotinib-refractory disease). Icotinib works by competitively binding to the adenosine triphosphate (ATP) binding site of the EGFR tyrosine kinase, thereby blocking downstream signaling pathways involved in cell proliferation and survival. The chemotherapy components exert cytotoxic effects through microtubule stabilization (docetaxel) or inhibition of folate-dependent enzymes required for DNA synthesis (pemetrexed).

Brand names

ConmanaTaxotereAlimta

Other names

icotinib plus chemotherapyicotinib in combination with chemotherapyicotinib + docetaxelicotinib + pemetrexed